Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Thu, 16th May 2013 06:53
May 16 (Reuters) - Hikma Pharmaceuticals Plc raisedits full-year revenue forecast, saying its generic antibioticdoxycycline was generating revenue ahead of its expectations.
The company said it expected group revenue to rise about 13percent in 2013, up from previous forecast of around 10 percent
Hikma reported revenue of $1.11 billion in 2012.
(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...
Read moreWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...
Read more
(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read more
BROKER RATINGS: Exane BNP downgrades three property companies
Read moreLONDON MARKET CLOSE: Stocks close out impressive April to end higher
Read moreTOP NEWS: Hikma Pharma confident after promising start to year
Read moreLONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises
Read more(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreLONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets
Read moreHikma resumes asthma drug launch, Vectura pays special dividend
Read moreLONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition
Read moreLONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance
Read more(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.
Read more
Last checked at